

Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, Jayprakash Road, Andheri (West), P. O. Box. 37396, Mumbai - 400 058. Phone: 67 603,603 (100 Lines) Fax: 91-22-6694 3127 www.jenburkt.com

Standalone Unaudited Financial Results for the Quarter & Nine months ended on 31.12.13

PART-I (Rs. in Lacs except per share data) Quarter Ended 9 Month Ended Year Ended **Particulars** Unaudited Unaudited Audited No. 31.12.13 30.09.13 31.12.12 31.12.13 31.12.12 31.03.13 **Income from Operations** (a) Net Sales/Income from Operations 1948.38 1974.87 1762.80 5626.8 5207.85 6927.00 (b) Other Operating Income 0.00 0.78 0.00 2.15 0.00 7.25 5207.85 Total Income from Operations (Net) 1948.38 1975.65 1762.80 5628.95 6934.25 2 Expenses (a) Cost of Materials Consumed 716.39 623.36 642.37 1806.70 1832.83 2362.93 0.00 0.00 (b) Purchases of Stock in Trade 0.12 0.00 0.90 11.22 -63.96 14.39 (c) Changes in Inventories of Finished Goods, Work-in--126.7161.05 -115.18 progress and Stock-in-Trade -88.62 (d) Employee benefits Expense 429.71 410.06 422.22 1273.81 1248.73 1580.66 37.50 39.00 24.00 112.50 74.00 148.29 (e) Depreciation and amortisation Expense (f) Other Expenses 614.60 543.40 551.02 1658.18 1517.98 2056.93 Total Expenses 1671.49 1676.87 1575.77 4865.58 4559.26 6071.41 3 Profit from Operations before other income, finance cost and exceptional items (1-2) 276.89 298.78 187.03 763.37 648.59 862.84 89.65 Other Income 51.76 36.79 37.41 55.92 111.95 Profit from Ordinary activities before finance costs and exceptional items (3+4) 328.65 335.57 224.44 853.02 704.51 974.79 Finance Cost 58.24 20.83 129.27 58.11 93.80 8.44 6 Profit from ordinary activities after finance cost but 880.99 before exceptional items (5-6) 270.41 314.74 216.00 723.75 646.40 8 Exceptional Income 0.00 0.90 0.00 0.90 0.00 1.39 Profit from Ordinary activities before tax (7+8) 646.40 882.38 270.41 315.64 216.00 724.65 75.00 85.00 72.00 205.00 192.00 260.85 10 Tax Expense 454.40 621.53 11 Net Profit from Ordinary activities after tax (9-10) 195.41 230.64 144.00 519.65 0.00 12 Extra ordinary items 0.00 0.00 0.00 0.00 0.00 13 Net Profit for the period (11+12) 195.41 230.64 144.00 519.65 454.40 621.53 14 Paid-up Equity Share Capital (face value of Rs.10/- each.) 464.93 464.93 464.93 464.93 464.93 464.93 0.00 0.00 15 Reserves and surplus 0.00 0.00 0.00 1800.17 16 Earnings per share (EPS) EPS (before & after extra ordinary items- Basic & Diluted) 4.20 4.96 3.10 11.18 9.77 13.37

Contd...2/-



Regd. Office: 93, Jayprakash Road, Andheri (West), P.O. Box. 37396, Mumbai - 400 058. • Phone: 67 603 603 (100 Lines) • Fax: 91-22-6694 3127 www.jenburkt.com

*** 2 ***

PART-II INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2013

		Quarter Ended			9 months ended		Year Ended
Sr. No.	Particulars	31.12.13	30.09.13	31.12.12	31.12.13	31.12.12	31.03.13
110.	1 A 1 O 2 A 1	Unaudited					Audited
A.	Particulars of Shareholding			1	4		
1	Public shareholding					1	7
1	- Number of shares	2479955	2486458	2517227	2479955	2517227	2500928
-	- Percentage of shareholding	53.34	53.48	54.14	53.34	54.14	53.79
2	Promoters and Promoter Group Shareholding				- n		
	a) Pledged / Encumbered			2 1			
	- Number of shares	0	0	. 0	0	0	0
	 Percentage of shares (as a % of the total shareholding of promoter and promoter group) Percentage of shares (as a % of the total share 	0	0	0	0	0	0
-	capital of the company) b) Non - encumbered	1 2 #1		# 10 E			
-	- Number of shares	2169345	2162842	2132073	2169345	2132073	2148372
	 Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) 	100.00	. 100.00	100.00	100.00	100.00	100.00
	 Percentage of shares (as a % of the total share capital of the company) 	46.66	46.52	45.86	46.66	45.86	46.21
	. Particulars	. Quarter ended on 31.12.2013					
В	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	Nil					
	Received during the quarter	1					
	Disposed of during the quarter						
	Remaining unresolved at the end of the quarter	Nil					

Notes:

- 1 The above unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 29.01.2014.
- 2 The Limited Review of the above results has been carried out by the Statutory Auditors.
- 3 The Company is dealing exclusively in Pharmaceuticals Business Segment, hence segmentwise presentation of financial results is not required.
- 4 Prior period figures have been rearranged / regrouped wherever necessary for comparative purposes.

By order of the Board,

For Jenburkt Pharmaceuticals Ltd.

Place: Mumbai Date: 29/01/2014

(Ashish U. Bhuta)

Chairman and Managing Director.